Biotech Co.* (Country; Symbol)

Pharma Co. (Country)


Terms/Details (Date)

Alliance Pharmaceutical Corp. (OTC BB:ALLP)

IL Yang Pharmaceutical Co. Ltd. (South Korea)

IL Yang got exclusive rights to distribute and commercialize Oxygent in South Korea

Alliance would get royalties from sales of the blood substitute, and milestones for regulatory progress in the U.S. and Europe (4/19)

Amylin Pharmaceuticals Inc. (AMLN)

Reliant Pharmaceuticals Inc.

Amylin will co-promote Reliant's products for cholesterol management and hypertension

The deal is expected to allow Amylin to leverage its sales efforts in diabetes; terms were not disclosed (4/8)

Artus GmbH* (Germany)

Abbott Laboratories

Expanded Abbott's distribution rights to all of Artus' nucleic acid-based diagnostics for use on Applied Biosystems instruments

Abbott is expanding the menu of tests it offers by adding Artus tests for several infectious diseases, which it will offer on the Applied Biosystems platform (4/14)

AVAX Technologies Inc. (OTC BB:AVXT)

OPi SAS (France)

Manufacturing alliance between AVAX unit Genopoeitic and OPi unit Opisodia SAS

AVAX is getting $1.5M for each of the next two years under the deal in which products for both companies will be produced (2/24)

Cartagen Molecular Systems Inc.*

Entest Japan Inc. (Japan)

Deal to develop a market presence for Cartagen's nucleic acid- separation products in Japan

Terms of the deal were not disclosed (3/9)

Chiral Quest Inc. (OTC BB:CQST)

Strem Chemicals Inc.

Several of Chiral Quest's ligand products

Strem Chemicals was named a distributor of the products (3/8)

Chromos Molecular Systems Inc. (Canada; TSE:CHR)

Lonza Biologics plc (UK)

Extended agreement providing Lonza nonexclusive access to Chromos' ACE System for evaluation in contract manufacturing

The extension runs to 4Q:04, and carries an option to license Chromos' ACE System with Lonza's GS System for use in cellular protein production (3/30)

Cobra Bio- manufacturing plc (UK; LSE:CBF)

AstraZeneca plc (UK)

Cobra will supply Astra- Zeneca licenses to DNA manufacturing technology

AstraZeneca will use the technology in support of identification and evaluation of drug targets; terms were not disclosed (3/30)

Diversa Inc. (DVSA)

Fermic SA de CV (Mexico)

Fermic will provide manufacturing capacity for production of Diversa's enzyme products

Diversa will co-invest in certain capital equipment in exchange for credits for manufacturing services; specific terms of the long-term deal were not disclosed (2/23)

EraGen Biosciences Inc.*

Inter Medico (Canada)

Inter Medico will distribute EraGen's molecular diagnostic products in Canada

Inter Medico's rights are exclusive in Canada; terms were not disclosed (3/15)

GlycoFi Inc.*

Eli Lilly and Co.

Deal to evaluate GlycoFi's yeast-based platform for producing an undisclosed protein

Lilly will support the effort; terms of the deal were not disclosed (4/8)

GTC Biotherapeutics Inc. (GTCB)

Laureate Pharma LP

Companies will coordinate efforts to provide recombinant protein production services

No initial payments were made in the deal, terms of which were not disclosed (3/9)

Immtech International Inc. (AMEX:IMM)

Cambrex Charles City Inc.

Agreement for Cambrex to develop an enhanced process for manufacturing DB289, a Phase II drug in malaria and other infectious diseases

Cambrex is expected to manufacture the substance in bulk after developing the synthesis method; terms were not dis- closed (3/17)

Interleukin Genetics Inc. (OTC BB:ILGN)

Access Business Group International LLC (subsidiary of Alticor Inc.)

Distribution agreement for DNA- ased risk-assessment tests

The deal with Access triggered a $2M payment from Alticor to Interleukin Genetics under a deal they entered in March 2003 (3/16)

Jerini AG* (Germany)

Bachem AG (Switzerland)

Agreement for the production and supply of Jerini's Icatibant, a peptidomimetic in Phase II

Bachem will provide manufacturing services for the bradykinin antagonist under undisclosed terms (3/18)

Labopharm Inc. (Canada; TSE:DDS)

Hexal AG (Germany)

Hexal gets the the right to market Labopharm's formulation of tramadol in Germany

Labopharm is responsible for obtaining regulatory approval in Germany; terms of the revenue-sharing deal were not disclosed (3/31)

Large Scale Biology Corp. (LSBC)

Sigma-Aldrich Fine Chemicals

Manufacturing and distribution deal for LSBC's plant-produced recombinant aprotinin product Apronexin

LSBC will manufacture the protease inhibitor and Sigma-Aldrich will distribute it to the R&D, cell culture and manufacturing markets under the multiyear deal (3/4)

Ligand Pharmaceuticals Inc. (LGND)

NV Organon (the Netherlands)

Companies will expand their sales efforts related to the pain drug Avinza

They will increase sales calls 50% and establish a specific effort to cover the long-term care/hospice segment of the market (3/31)

Ligand Pharmaceuticals Inc. (LGND)

Hollister-Stier Laboratories LLC

Hollister-Stier will provide fill/ finish work for Ontak and a second- generation formulation

The five-year deal was made with Ligand subsidiary Seragen Inc., and can be extended two years by Ligand; terms were not disclosed (3/3)

Ligand Pharmaceuticals Inc. (LGND)

Cardinal Health Inc.

Cardinal will manufacture and package Ligand's Avinza

Ligand has an option to extend the five- year deal two additional years; terms were not disclosed (3/3)

Microbia Inc.*

Teva Pharmaceutical Industries Ltd. (Israel)

Multiyear, multiproduct expansion of deal to develop improved biomanufacturing processes

The deal centers on Microbia's Precision Engineering technology; Teva will fund Microbia's efforts and make undisclosed milestone and royalty payments (3/29)

Micromet AG* (Germany)

Boehringer Ingelheim GmbH (Germany)

Deal for the process development and production of Micromet's fully human MT201 antibody

BI will supply material for clinical trials and future commercialization for the Phase II prostate cancer product; Micromet may license BI's high- xpression technology for manufacturing MT201, while BI gets an option for commercial manufacturing of MT201 (2/25)

NeoPharm Inc. (NEOL)

Diosynth Biotechnology (unit of Akzo Nobel NV)

Diosynth will manufacture interleukin-13-PE38QQR for NeoPharm's Phase III trials

The drug is being tested in glioblastoma multiforme; terms of the deal were not disclosed (4/7)

NovImmune SA* (Switzerland)

Lonza Group AG (Switzerland)

Deal for the production and supply of clinical-grade monoclonal antibody drugs

Lonza will manufacture the products of NovImmune and its partners, all the way to marketing; terms were not disclosed (2/20)

Provalis plc (UK; LSE:PRO)

Edmond Pharma SpA (Italy)

Deal for Provalis to distribute the mucolytic agent Erdotin in the UK and Ireland

Provalis is paying €200,000 toward development and regulatory costs, against certain regulatory milestones; the product has been available in other Eurpopean markets (4/19)

Raven Biotechnologies Inc.*

AppTec Laboratory Services Inc.

Deal for process development and manufacturing of Raven's RAV12 monoclonal antibody

The deal gives Raven flexibility regarding preclinical and future clinical supplies of the cancer product; terms were not dis- closed (4/14)

RNAx GmbH* (Germany)

Funakoshi Ltd. (Japan)

Funakoshi will be exclusive agent for RNAx in Japan

The deal relates to RNAx services for validation of siRNA oligonucleotides and genetic targets based on RNAi technology (3/26)

Seattle Genetics Inc. (SGEN)

Abbott Laboratories

Deal for the manufacturing of Seattle Genetics' SGN-30 monoclonal antibody product

Abbott will perform scale-up and GMP manufacturing for trials, and would supply commercial-grade material to support any sales; terms were not disclosed. (2/24)

Y's Therapeutics (Japan)

Lonza Group Ltd. (Switzerland)

Collaboration on cell line construction of a humanized monoclonal antibody for Y's YSCMA program in cancer and immune diseases

Y's gets access to Lonza's GS Gene Expression System for creating a cell line and to antibody manufacturing expertise; terms were not disclosed (4/6)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.